Omega Therapeutics Strengthens Board of Directors with Appointment of R&D Veteran Elliott M. Levy, M.D.

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., May 20, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines, today announced the appointment of Elliott...

Click to view original post